title: Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins.
abstract: The endocannabinoid (EC) system regulates food intake and energy metabolism. Cannabinoid receptor type 1 (CB1) antagonists show promise in the treatment of obesity and its metabolic consequences. Although the reduction in adiposity resulting from therapy with CB1 antagonists may not account fully for the concomitant improvements in dyslipidemia, direct effects of overactive EC signaling on plasma lipoprotein metabolism have not been documented. The present study used a chemical approach to evaluate the direct effects of increased EC signaling in mice by inducing acute elevations of endogenously produced cannabinoids through pharmacological inhibition of their enzymatic hydrolysis by isopropyl dodecylfluorophosphonate (IDFP). Acute IDFP treatment increased plasma levels of triglyceride (TG) (2.0- to 3.1-fold) and cholesterol (1.3- to 1.4-fold) in conjunction with an accumulation in plasma of apolipoprotein (apo)E-depleted TG-rich lipoproteins. These changes did not occur in either CB1-null or apoE-null mice, were prevented by pretreatment with CB1 antagonists, and were not associated with reduced hepatic apoE gene expression. Although IDFP treatment increased hepatic mRNA levels of lipogenic genes (Srebp1 and Fas), there was no effect on TG secretion into plasma. Instead, IDFP treatment impaired clearance of an intravenously administered TG emulsion, despite increased postheparin lipoprotein lipase activity. Therefore, overactive EC signaling elicits an increase in plasma triglyceride levels associated with reduced plasma TG clearance and an accumulation in plasma of apoE-depleted TG-rich lipoproteins. These findings suggest a role of CB1 activation in the pathogenesis of obesity-related hypertriglyceridemia and underscore the potential efficacy of CB1 antagonists in treating metabolic disease.
authors.affiliation: Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
authors.forename: Maxwell A
authors.initials: MA
authors.lastname: Ruby
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Nomura
authors.forename: Carolyn S S
authors.initials: CS
authors.lastname: Hudak
authors.forename: Lara M
authors.initials: LM
authors.lastname: Mangravite
authors.forename: Sally
authors.initials: S
authors.lastname: Chiu
authors.forename: John E
authors.initials: JE
authors.lastname: Casida
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Krauss
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism*; D001095:Arachidonic Acids / Q000378:metabolism; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D063388:Endocannabinoids; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D005989:Glycerides / Q000378:metabolism; D008049:Lipase / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D051379:Mice; D063065:Organophosphonates / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
chemical_list: D001057:Apolipoproteins E; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D004791:Enzyme Inhibitors; D005989:Glycerides; D008055:Lipids; D008074:Lipoproteins; D063065:Organophosphonates; D043884:Receptor, Cannabinoid, CB1; D014280:Triglycerides; C094503:glyceryl 2-arachidonate; D002784:Cholesterol; D008049:Lipase
references.citation: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
references.pmid: 10318961
references.citation: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
references.pmid: 11470906
references.citation: Life Sci. 1998;63(8):PL113-7
references.pmid: 9718088
references.citation: Chem Biol. 2007 Dec;14(12):1347-56
references.pmid: 18096503
references.citation: Ann Clin Biochem. 1981 May;18(Pt 3):177-81
references.pmid: 7283369
references.citation: Nat Rev Neurosci. 2003 Nov;4(11):873-84
references.pmid: 14595399
references.citation: Cell Metab. 2007 Apr;5(4):279-91
references.pmid: 17403372
references.citation: JAMA. 2006 Feb 15;295(7):761-75
references.pmid: 16478899
references.citation: Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
references.pmid: 12399252
references.citation: Nature. 2001 Apr 12;410(6830):822-5
references.pmid: 11298451
references.citation: J Clin Invest. 1998 Feb 15;101(4):905-12
references.pmid: 9466986
references.citation: J Clin Invest. 2005 May;115(5):1298-305
references.pmid: 15864349
references.citation: Biochem Cell Biol. 1986 Aug;64(8):826-35
references.pmid: 3768169
references.citation: Metabolism. 1990 Feb;39(2):155-60
references.pmid: 2299988
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4471-5
references.pmid: 1584779
references.citation: J Nutr. 1988 Aug;118(8):932-40
references.pmid: 3404286
references.citation: Eur Heart J. 2008 Jul;29(14):1761-71
references.pmid: 18417461
references.citation: Int J Obes Relat Metab Disord. 2004 Apr;28(4):640-8
references.pmid: 14770190
references.citation: Lancet. 2006 Nov 11;368(9548):1660-72
references.pmid: 17098084
references.citation: Toxicol Sci. 2003 Nov;76(1):131-7
references.pmid: 12944586
references.citation: J Biol Chem. 2006 Jan 13;281(2):934-44
references.pmid: 16272564
references.citation: Clin Chem. 2008 Aug;54(8):1307-16
references.pmid: 18515257
references.citation: Obesity (Silver Spring). 2008 Mar;16(3):553-65
references.pmid: 18239598
references.citation: J Lipid Res. 1998 Aug;39(8):1661-8
references.pmid: 9717727
references.citation: Int J Obes (Lond). 2005 Jul;29(7):755-9
references.pmid: 15809662
references.citation: Proc Natl Acad Sci U S A. 1994 May 10;91(10):4431-5
references.pmid: 8183926
references.citation: JAMA. 2007 Sep 19;298(11):1300-11
references.pmid: 17878422
references.citation: Diabetes. 2006 Nov;55(11):3053-60
references.pmid: 17065342
references.citation: JAMA. 2002 Dec 4;288(21):2709-16
references.pmid: 12460094
references.citation: N Engl J Med. 2005 Nov 17;353(20):2121-34
references.pmid: 16291982
references.citation: J Clin Invest. 2003 Aug;112(3):423-31
references.pmid: 12897210
references.citation: J Clin Invest. 1997 Jun 1;99(11):2672-81
references.pmid: 9169497
references.citation: FASEB J. 2005 Sep;19(11):1567-9
references.pmid: 16009704
references.citation: Cell Metab. 2008 Mar;7(3):227-35
references.pmid: 18316028
references.citation: Chem Rev. 2008 May;108(5):1687-707
references.pmid: 18429637
references.citation: J Lipid Res. 1995 Oct;36(10):2174-84
references.pmid: 8576643
references.citation: Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1006-14
references.pmid: 15087308
references.citation: Nat Chem Biol. 2008 Jun;4(6):373-8
references.pmid: 18438404
references.citation: Diabetes. 2005 Oct;54(10):2838-43
references.pmid: 16186383
references.citation: Lancet. 2005 Apr 16-22;365(9468):1389-97
references.pmid: 15836887
references.citation: J Lipid Res. 2005 Sep;46(9):2023-8
references.pmid: 15995182
references.citation: PLoS One. 2008 Jun 18;3(6):e2503
references.pmid: 18560564
references.citation: J Lipid Res. 2002 Dec;43(12):2136-45
references.pmid: 12454276
references.citation: Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):442-8
references.pmid: 16373604